Efficacy and safety of febuxostat in renal transplant recipients with hyperuricemia

Objective To assess the efficacy and safety of febuxostat in the treatment of hyperuricemia in renal transplant recipients. Methods A total of 124 renal transplant patients with hyperuricemia receiving febuxostat between June 2016 and July 2018 were retrospectively analyzed. Uric acid (UA), liver function and renal function parameters before and 3 months after treatment were compared. Adverse events, recipient and renal allograft survival were recorded throughout the follow-up period. Results Serum level of uric acid significantly decreased after 3-month treatment (P<0.001). And 66.1 % of them achieved target UA level at Month 3 after dosing. Estimated glomerular filtration rate (eGFR) was maintained. No severe adverse event was observed. All recipient and renal grafts survived during the follow-up period. Conclusions Febuxostat is both effective and safe in the treatment of hyperuricemia in renal transplant. Key words: Renal transplantation; Hyperuricemia; Efficacy